
    
      This is a 24-month, open-label, multicenter, interventional, single-arm study to collect
      efficacy and, safety of oral fingolimod 0.5 mg/day in approximately 100 relapsing multiple
      sclerosis (RMS) subjects in China.

      The study will consist of three Phases:

      Screening (up to 1 month): After signing informed consent, subjects will enter a Screening
      Phase to determine eligibility according to inclusion and exclusion criteria.

      Treatment Period (24 months): On visit Day 1, all eligibility criteria will be confirmed,
      including a pre-dose ECG and vital signs. The first dose of study drug will be taken in the
      clinic on Day 1 and the subject will be monitored for 6 hours after the first dose
      administration before discharge. Participants will return to site for evaluation at month 1
      and then every three months until the end of treatment up to 24 months.

      Follow Up (2 months): Subjects who completed Treatment Period or discontinued from treatment
      will return for the Follow-up visit 2 months after the last dose of study drug.
    
  